Key Points
For more information, please visit Jiayi Pharmaceutical.
Question What is the effect of ivermectin on duration of symptoms in adults with mild COVID-19?
Findings In this randomized clinical trial that included 476 patients, the duration of symptoms was not significantly different for patients who received a 5-day course of ivermectin compared with placebo (median time to resolution of symptoms, 10 vs 12 days; hazard ratio for resolution of symptoms, 1.07).
Meaning The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand effects on other clinically relevant outcomes.
Abstract
Importance Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit.
Objective To determine whether ivermectin is an efficacious treatment for mild COVID-19.
Design, Setting, and Participants Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state&#;s health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, , and followed up through December 21, .
Intervention Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n&#;=&#;200) or placebo (n&#;=&#;200).
Main Outcomes and Measures Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected.
Results Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P&#;=&#;.53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group).
Conclusion and Relevance Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.
Trial Registration ClinicalTrials.gov Identifier: NCT
Introduction
Therapeutic approaches are needed to improve outcomes in patients with COVID-19. Ivermectin, a widely used drug with a favorable safety profile,1 is thought to act at different protein-binding sites to reduce viral replication.2-5 Because of evidence of activity against SARS-CoV-2 in vitro6 and in animal models,7,8 ivermectin has attracted interest in the global scientific community9 and among policy makers.10 Several countries have included ivermectin in their treatment guidelines,11-13 leading to a surge in the demand for the medication by the general population and even alleged distribution of veterinary formulations.14 However, clinical trials are needed to determine the effects of ivermectin on COVID-19 in the clinical setting.
Viral replication may be particularly active early in the course of COVID- and experimental studies have shown antiviral activity of ivermectin in early stages of other infections.4 The hypothesis of this randomized trial (EPIC trial [Estudio Para Evaluar la Ivermectina en COVID-19]) was that ivermectin would accelerate recovery in patients with COVID-19 when administered during the first days of infection.
Methods
Study Design and Patients
This study was approved by the Colombian Regulatory Agency (INVIMA No. PI-CEP-), the independent ethics committees of Corporación Científica Pediátrica, and collaborating hospitals in Cali, Colombia, and conducted in accordance with Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all patients. Full details of the trial can be found in the protocol (Supplement 1).
This double-blind, randomized trial of ivermectin vs placebo was conducted from July 15 to December 21, , by Centro de Estudios en Infectología Pediátrica in Cali. Study candidates were identified from the state&#;s health department electronic database of all patients with a positive result from a SARS-CoV-2 reverse transcriptase&#;polymerase chain reaction or antigen test performed in any of the Colombian National Institute of Health&#;authorized laboratories in the city of Cali.
Potential study participants were identified and selected by simple random sampling from the state&#;s database. Adult men and non&#;pregnant or breast-feeding women were eligible if their symptoms began within the previous 7 days and they had mild disease, defined as being at home or hospitalized but not receiving high-flow nasal oxygen or mechanical ventilation (invasive or noninvasive). Patients were excluded if they were asymptomatic, had severe pneumonia, had received ivermectin within the previous 5 days, or had hepatic dysfunction or liver function test results more than 1.5 times the normal level. Details of selection criteria can be found in the protocol (Supplement 1). Health disparities by race/ethnicity have been reported in COVID-19 infections.16,17 Hence, information on this variable was collected by study personnel based on fixed categories as selected by the study participants.
Randomization
Eligible patients were randomly assigned in a 1:1 ratio to receive either oral ivermectin or placebo in solution for 5 days. Patients were randomized in permuted blocks of 4 in a randomization sequence prepared by the unblinded pharmacist in Microsoft Excel version 19.0 who provided masked ivermectin or placebo to a field nurse for home or hospital patient visits. Allocation assignment was concealed from investigators and patients.
Interventions
Study patients received 300 μg/kg of body weight per day of oral ivermectin in solution or the same volume of placebo for 5 days. Ivermectin was provided by Tecnoquímicas SA in bottles of 0.6% solution for oral administration. Patients were asked to take the investigational product on an empty stomach, except on the first study day, when it was administered after screening and randomization procedures took place.
Up to August 26, , the placebo was a mixture of 5% dextrose in saline and 5% dextrose in distilled water, after which placebo was a solution with similar organoleptic properties to ivermectin provided by the manufacturer. Because blinding could be jeopardized due to the different taste and smell of ivermectin and the saline/dextrose placebo, only 1 patient per household was included in the study until the manufacturer&#;s placebo was available. Bottles of ivermectin and placebo were identical throughout the study period to guarantee double-blinding.
Procedures
A study physician contacted potential study participants by to verify selection criteria for eligibility and obtain informed consent. Patients were then visited at home or in hospital by a study nurse who drew blood for liver enzyme evaluations and performed a urine pregnancy test. Eligible patients were revisited by a study nurse for enrollment, documentation of baseline demographic and clinical information, and dispensing of the investigational product. Investigational product was left with the patient for self-administration on days 2 through 5. Subsequently, patients were contacted by by study staff on days 2 through 5, 8, 11, 15, and 21 for a structured interview. A study physician reviewed medical records of hospitalized patients to obtain the information required by the protocol. After study end (day 21), unused or empty investigational product bottles were collected to certify adherence. Data were entered into an electronic database and validated by the site&#;s quality management department.
Outcome Measures
The primary outcome was the time from randomization to complete resolution of symptoms within the 21-day follow-up period. The 8-category ordinal scale used in this trial has been used in different COVID-19 therapeutic trials18-20 and is recommended by the World Health Organization&#;s R&D Blueprint.21 It consists of the following categories: 0&#;=&#;no clinical evidence of infection; 1&#;=&#;not hospitalized and no limitation of activities; 2&#;=&#;not hospitalized, with limitation of activities, home oxygen requirement, or both; 3&#;=&#;hospitalized, not requiring supplemental oxygen; 4&#;=&#;hospitalized, requiring supplemental oxygen; 5&#;=&#;hospitalized, requiring nasal high-flow oxygen, noninvasive mechanical ventilation, or both; 6&#;=&#;hospitalized, requiring extracorporeal membrane oxygenation, invasive mechanical ventilation, or both; and 7&#;=&#;death. Time to recovery was defined as the first day during the 21 days of follow-up in which the patient reported a score of 0.
Secondary outcomes included the proportion of patients with clinical deterioration, defined as those with worsening by 2 points (from the baseline score on the 8-category ordinal scale) since randomization. Additional secondary outcomes were the clinical conditions as assessed by the 8-category ordinal scale on days 2, 5, 8, 11, 15, and 21; however, data for days 2 and 15 are not reported here. The proportion of patients who developed fever and the duration of fever since randomization and the proportion of patients who died were also reported. Proportions of patients with new-onset hospitalization in the general ward or intensive care unit or new-onset supplementary oxygen requirement for more than 24 hours were combined into a single outcome called escalation of care. Frequency of incident cases of escalation of care, as well as the duration in both treatment groups, was reported. Evaluation of adverse events (AEs) included solicited AEs, AEs leading to treatment discontinuation, and serious AEs. AEs were classified according to the National Cancer Institute&#;s Common Terminology Criteria for Adverse Events version 5.0.22
Post Hoc Analysis
Given that some patients&#; need for escalation of care was imminent when randomized, the frequency of incident cases of escalation of care occurring 12 or more hours after randomization and the duration up to day 21 in both treatment groups were reported. A comparison of the proportions of patients who required emergency department (ED) or telemedicine consultation was also performed.
Statistical Analysis
The primary outcome was originally defined as the time from randomization until worsening by 2 points on the 8-category ordinal scale. According to the literature, approximately 18% of patients were expected to have such an outcome.23 However, before the interim analysis, it became apparent that the pooled event rate of worsening by 2 points was substantially lower than the initial 18% expectation, requiring an unattainable sample size. Therefore, on August 31, , the principal investigator proposed to the data and safety monitoring board to modify the primary end point to time from randomization to complete resolution of symptoms within the 21-day follow-up period. This was approved on September 2, . The original sample size of 400 based on the log-rank test for the new primary end point was kept, using an ivermectin to placebo assignment ratio of 1:1. This would allow the detection of 290 events of interest (symptom resolution), assuming that 75% of patients would have the outcome of interest at 21 days,24 with a 2% dropout rate. This would provide an 80% power under a 2-sided type I error of 5% if the hazard ratio (HR) comparing ivermectin vs placebo is 1.4, corresponding to a 3-day faster resolution of symptoms in patients receiving ivermectin, assuming that time to resolution of symptoms is 12 days with placebo.24 With an HR of 1.4, 75% and 85% of patients in the placebo and ivermectin groups, respectively, would experience the outcome of interest at 21 days.
On October 20, , the lead pharmacist observed that a labeling error had occurred between September 29 and October 15, , resulting in all patients receiving ivermectin and none receiving placebo during this time frame. The study blind was not unmasked due to this error. The data and safety monitoring board recommended excluding these patients from the primary analysis but retaining them for sensitivity analysis. The protocol was amended to replace these patients to retain the originally calculated study power. The primary analysis population included patients who were analyzed according to their randomization group, but excluded patients recruited between September 29 and October 15, , as well as patients who were randomized but later found to be in violation of selection criteria. Patients were analyzed according to the treatment they received in the as-treated population (sensitivity analysis).
The primary end point of time from randomization to complete resolution of symptoms with ivermectin vs placebo was assessed by a Kaplan-Meier plot and compared with a log-rank test. The HRs and 95% CIs for the cumulative incidence of symptom resolution in both treatment groups were estimated using the Cox proportional hazards model. The proportional hazards assumption was tested graphically using a log-log plot and the test of the nonzero slope. There was no evidence to reject the proportionality assumption.
The time to complete resolution of symptoms was assessed after all patients reached day 21. Data for patients who died or lacked symptom resolution before day 21 were right-censored at death or day 21, respectively. Evaluation of the effect of the treatment in each study visit using the 8-point ordinal scale was estimated using the proportional odds ratio (OR) with its respective 95% CI with an ordinal logistic regression. The proportional odds assumption was met according to the Brant test. The 8-point ordinal scale was inverted in its score, where 0 corresponded to death and 7 to a patient without symptoms.
For sensitivity analysis, primary and secondary end points were compared in the as-treated population.
Clustered standard errors were estimated to adjust for the correlation between multiple patients from the same household. Statistical significance was set at P&#;<&#;.05, and all tests were 2-tailed. Because of the potential for type I error due to multiple comparisons, findings for analyses of secondary end points should be interpreted as exploratory. Statistical analyses were done with Stata version 16.0 (StataCorp). Bootstrapping 95% CIs for differences of medians were calculated with R statistical package version 3.6.3 (The R Foundation).
Results
Patients
Of the 476 patients who underwent randomization, 238 were assigned to receive ivermectin and 238 to receive placebo (Figure 1). Seventy-five patients were randomized between September 29 and October 15, , and were excluded from the primary analysis population but remained in the as-treated population. Three patients were excluded from all analyses because they were identified as ineligible after randomization (1 asymptomatic patient and 2 who received ivermectin within 5 days prior to enrollment). The primary analysis population included 398 patients (200 allocated to ivermectin and 198 to placebo).
Patients in both groups were balanced in demographic and disease characteristics at baseline (Table 1; eTable 1 in Supplement 2). The median age of patients in the primary analysis population was 37 years (interquartile range [IQR], 29-48), 231 (58%) were women, and 316 (79%) did not have any known comorbidities at baseline. At randomization, the median National Early Warning Score 2 was 3 (IQR, 2-4) and most patients (n&#;=&#;232, 58.3%) were at home and able to perform their routine activities. The most common symptoms were myalgia (310 patients, 77.9%) and headache (305 patients, 76.6%), followed by smell and taste disturbances (223 [56%] and 199 [50%], respectively) and cough (211 patients, 53%), which was most commonly dry (181 patients, 45.5%) (eTable 2 in Supplement 2).
Baseline characteristics of the 75 patients who received ivermectin but were excluded from the primary analysis were not significantly different from the 398 remaining patients in the cohort (eTables 1 and 3 in Supplement 2).
Primary Outcome
Time to resolution of symptoms in patients assigned to ivermectin vs placebo was not significantly different (median, 10 days vs 12 days; difference, &#;2 days [IQR, &#;4 to 2]; HR for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P&#;=&#;.53) (Figure 2 and Table 2). In the ivermectin and placebo groups, symptoms resolved in 82% and 79% of patients, respectively, by day 21 (Table 2).
The type of placebo that patients received did not affect the results (HR for ivermectin vs dextrose in saline: 1.14 [95% CI, 0.83-1.55]; HR for ivermectin vs manufacturer&#;s placebo: 1.07 [95% CI, 0.85 to 1.34] (eFigure 1 in Supplement 2).
Similar results were observed in the as-treated population (eFigure 2 and eTable 4 in Supplement 2).
Secondary Outcomes
Few patients had clinical deterioration of 2 or more points in the ordinal 8-point scale, and there was no significant difference between the 2 treatment groups (2% in the ivermectin group and 3.5% in the placebo group; absolute difference, &#;1.53 [95% CI, &#;4.75 to 1.69]). The OR for deterioration in ivermectin vs placebo groups was 0.56 (95% CI, 0.16 to 1.93) (Table 2).
The odds of improving the score in the ordinal scale were not significantly different between both treatment groups, as determined by proportional odds models (eFigure 3 and eTable 5 in Supplement 2).
There was no significant difference in the proportion of patients who required escalation of care in the 2 treatment groups (2% with ivermectin, 5% with placebo; absolute difference, &#;3.05 [95% CI, &#;6.67 to 0.56]; OR, 0.38 [95% CI, 0.12 to 1.24]). The length of time during which patients required escalation of care in the ivermectin vs placebo groups was not significantly different (median difference, 7 days [IQR, &#;5.0 to 16.5]). The proportions of patients who developed fever during the study period were not significantly different between the 2 treatment groups (absolute difference of ivermectin vs placebo, &#;2.61 [95% CI, &#;8.31 to 3.09]; OR, 0.73 [95% CI, 0.37 to 1.45]), nor was the duration of fever (absolute difference of ivermectin vs placebo, &#;0.5 days [95% CI, &#;1.0 to 2.0]) (Table 2). One patient in the placebo group died during the study period. No data were missing for the primary or secondary outcomes. See eTables 4 and 6 in Supplement 2 for the results in the as-treated population.
Post Hoc End Points and Analyses
After excluding 4 patients who required hospitalization within 12 hours after randomization (median, 3.25 hours [IQR, 2-6]), there were 4 patients (2%) in the ivermectin group and 6 (3%) in the placebo group who required escalation of care (absolute difference, &#;1.0 [95% CI, &#;4.11 to 2.05]; OR, 0.65 [95% CI, 0.18 to 2.36]) (Table 2).
The proportions of patients who sought medical care (ED or telemedicine consultation) were not significantly different between the 2 treatment groups (8.0% in the ivermectin group and 6.6% in the placebo group; absolute difference, 1.43 [95% CI, &#;3.67 to 6.54]; OR, 1.24 [95% CI, 0.56 to 2.74]) (Table 2). See eTable 4 in Supplement 2 for the results in the as-treated population.
Adverse Events
For more China Ivermectin Supplierinformation, please contact us. We will provide professional answers.
A total of 154 patients (77%) in the ivermectin group and 161 (81.3%) in the placebo group reported AEs between randomization and day 21. Fifteen patients (7.5%) in the ivermectin group vs 5 patients (2.5%) in the placebo group discontinued treatment due to an AE. Serious AEs developed in 4 patients, 2 in each group, but none were considered by the investigators to be related to the trial medication (Table 3; eTable 7 in Supplement 2).
Discussion
In this double-blind, randomized trial of symptomatic adults with mild COVID-19, a 5-day course of ivermectin vs placebo initiated in the first 7 days after evidence of infection failed to significantly improve the time to resolution of symptoms.
Interest in ivermectin in COVID-19 therapy began from an in vitro study that found that bathing SARS-CoV-2&#;infected Vero-hSLAM cells with 5-μM ivermectin led to an approximately -fold reduction in viral RNA.8 However, pharmacokinetic models indicated that the concentrations used in the in vitro study are difficult to achieve in human lungs or plasma,25 and inhibitory concentrations of ivermectin are unlikely to be achieved in humans at clinically safe doses.26 Despite this, a retrospective study using logistic regression and propensity score matching found an association between 200 μg/kg of ivermectin in a single dose (8% of patients received a second dose) and improved survival for patients admitted with severe COVID-19.27 The contrast with the findings in this trial may be related to differences in patient characteristics, exposures and outcomes that were measured, or unmeasured confounders in the observational study. To our knowledge, preliminary reports of other randomized trials of ivermectin as treatment for COVID-19 with positive results have not yet been published in peer-reviewed journals.28-31
Daily doses were used in this trial because pharmacokinetic models have shown higher lung concentrations with daily rather than intermittent dosing,32 and have proven to be well tolerated.33,34 In addition, the US Food and Drug Administration&#;approved dose for the treatment of helminthic diseases (200 μg/kg) showed clinical benefit in an observational study,27 supporting a hypothesis that higher doses could be clinically relevant.
This study did not find any significant effect of ivermectin on other evaluated measures of clinical benefit for the treatment of COVID-19. Although a numerically smaller proportion of ivermectin-treated patients required escalation of care (2.0% with ivermectin vs 5.0% with placebo), the difference was not statistically significant and was further attenuated in a post hoc analysis after excluding 4 patients who were hospitalized at a median time of 3.25 hours after randomization. In addition, ivermectin did not reduce ED or consultations, further supporting the lack of efficacy for these outcomes. However, the relatively young and healthy study population rarely developed complications, rendering the study underpowered to detect such effects. Therefore, the ability of ivermectin to prevent the progression of mild COVID-19 to more severe stages would need to be assessed in larger trials.
The study was sufficiently powered to detect faster resolution of symptoms in patients soon after they became apparent, and no significant difference was identified. However, the study population was relatively young, with few comorbidities and with liver enzyme levels less than 1.5 times the normal level, so the findings may be generalizable only to such populations.
Cumulatively, the findings suggest that ivermectin does not significantly affect the course of early COVID-19, consistent with pharmacokinetic models showing that plasma total and unbound ivermectin levels do not reach the concentration resulting in 50% of viral inhibition even for a dose level 10-times higher than the approved dose.32
Limitations
This study has several limitations. First, the study was not conducted or completed according to the original design, and the original primary outcome to detect the ability of ivermectin to prevent clinical deterioration was changed 6 weeks into the trial. In the study population, the incidence of clinical deterioration was below 3%, making the original planned analysis futile. Ultimately, findings for primary and secondary end points were not significantly different between the ivermectin and placebo groups.
Second, the study was well-powered to detect an HR for resolution of symptoms of 1.4 in the ivermectin vs placebo groups, but may have been underpowered to detect a smaller but still clinically meaningful reduction in the primary end point.
Third, virological assessments were not included, but the clinical characteristics that were measured indirectly reflect viral activity and are of interest during the pandemic.
Fourth, the placebo used in the first 65 patients differed in taste and smell from ivermectin. However, patients from the same household were not included until the placebo with the same organoleptic properties was available, and the lack of effect of ivermectin on the primary outcome was similar when compared with either formulation of placebo.
Fifth, 2 secondary outcomes used an 8-category ordinal scale that in initial stages requires patient self-reporting and thus allows subjectivity to be introduced. Sixth, data on the ivermectin plasma levels were not collected. Seventh, as already noted, the study population was relatively young and results may differ in an older population.
Conclusions
Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.
Back to topArticle Information
Accepted for Publication: February 18, .
Published Online: March 4, . doi:10./jama..
Concept and design: López-Medina, López, Hurtado, Dávalos, Ramirez, Martínez, Díazgranados, Oñate, Chavarriaga.
Acquisition, analysis, or interpretation of data: López-Medina, Hurtado, Ramirez, Martínez, Oñate, Chavarriaga, Herrera, Parra, Libreros, Jaramillo, Avendaño, Toro, Torres, Lesmes, Rios, Caicedo.
Drafting of the manuscript: López-Medina, Hurtado, Dávalos, Chavarriaga, Caicedo.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: López-Medina, Ramirez.
Obtained funding: López-Medina, López.
Administrative, technical, or material support: Hurtado, Dávalos, Martínez, Díazgranados, Chavarriaga, Herrera, Parra, Libreros, Jaramillo, Avendaño, Toro, Torres, Lesmes, Rios, Caicedo.
Supervision: López-Medina, López, Oñate, Rios, Caicedo.
Conflict of Interest Disclosures: Dr López-Medina reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, and Janssen and personal fees from Sanofi Pasteur during the conduct of the study. Dr López reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, and Janssen and personal fees from Sanofi Pasteur during the conduct of the study. Dr Oñate reported receiving grants from Janssen and personal fees from Merck Sharp & Dohme and Gilead outside the submitted work. Dr Torres reported receiving nonfinancial support from Tecnoquímicas unrelated to this project during the conduct of the study. No other disclosures were reported.
Funding/Support: This study received an unrestricted grant from Centro de Estudios en Infectología Pediátrica (grant ScDi823).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: In addition to the authors, the following collaborators from Centro de Estudios en Infectología Pediátrica participated in the Estudio Para Evaluar la Ivermectina en COVID-19 (EPIC) trial:
Catalina De La Cruz, MD; Camilo Andrade; Iñigo Prieto, MD, MSc; Viviana Márquez, MD; Mary Luz Hernandez; Carlos Gonzalez, MD; Victoria Aguirre, RN; Gloria Tamayo; Leidy Gomez; Aracelly Romero; Socorro Mutis; Nidia Guaza; Eliana Valencia; James Riascos; Ovidio Maldonado; Laura Victoria, RN; Hilda Giraldo; Lina Solano, RN; Maria F. Collazos, RN; Elizabeth Toro, MD; Carlos Cortés, MD; Alexandra Sierra, MD; Carolina Ospina, MD; Diana P. Mazo, PharmD; Jhon J. Calderón; Jenny Yela, RN; Diego Rivera, RN; and Diana Suárez, PharmD.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We are grateful to the patients who participated in this trial; Erika Cantor, MSc, from the Institute of Statistics, Universidad de Valparaíso, Valparaíso, Chile, for her contribution during data analysis; Keith Veitch for his writing assistance; and Neal Alexander, PhD, from CIDEIM in Cali, Colombia, and Rodrigo DeAntonio, DrPH, from Cevaxin in Panamá City, Panamá, for their contribution during study planning. Ms Cantor and Mr Veitch received compensation for their roles in the study. Drs Alexander and DeAntonio did not receive compensation for their roles in the study. We thank Tecnoquímicas for its donation of the investigational product and placebo from August 26, , until the end of the trial.
References
CNN
&#;The US Food and Drug Administration has settled a lawsuit over some of its posts about ivermectin, including what may have been one of its more popular pandemic-era social media campaigns.
In August , to discourage people from using ivermectin to prevent or treat Covid-19, the FDA tweeted &#;You are not a horse. You are not a cow. Serious y&#;all. Stop It.&#; and posted a similar message on Instagram. The tweet got nearly 106,000 likes.
The antiparasitic drug, which is prescribed to treat neglected tropical diseases in humans like river blindness and scabies, can also be bought over-the-counter at livestock supply centers to help deworm animals such as horses and cows.
Some conservative outlets touted the drug as safe and effective against Covid even though the FDA and the World Health Organization encouraged people not to use it, saying it was ineffective against Covid and could even be dangerous if someone took too much.
Some conservative media personalities and lawmakers said information about the effectiveness of ivermectin was being downplayed because of its low price. It was also praised as a &#;miracle drug&#; by Dr. Pierre Kory, a pulmonologist and president of the Frontline COVID-19 Critical Care Alliance, who testified at a US Senate committee hearing in December . Even popular podcaster Joe Rogan, who took the drug along with several other medicines after testing positive for Covid, got into a spirited discussion with CNN Chief Medical Correspondent Dr. Sanjay Gupta about it at the time.
In August , the US Centers for Disease Control and Prevention sent a health advisory warning doctors and the public about the &#;rapid increase&#; in prescriptions for ivermectin and an increase in reports to poison centers about severe illness caused by the drug. Some people who took higher than recommended doses or used the animal formulation developed neurological symptoms, and some were hospitalized, studies show.
The FDA said in an to CNN on Wednesday that it &#;has chosen to resolve this lawsuit rather than continuing to litigate over statements that are between two and nearly four years old.&#;
The agency added that it has &#;not admitted any violation of law or any wrongdoing, disagrees with the plaintiffs&#; allegation that the agency exceeded its authority in issuing the statements challenged in the lawsuit, and stands by its authority to communicate with the public regarding the products it regulates.
&#;FDA has not changed its position that currently available clinical trial data do not demonstrate that ivermectin is effective against COVID-19. The agency has not authorized or approved ivermectin for use in preventing or treating COVID-19.&#;
The lawsuit was filed in June by Drs. Rober Apter, Mary Talley Bowden and Paul Marik against the FDA, the US Department of Health and Human Services and their leaders. It claimed that the agencies were interfering with their ability to practice medicine by overstepping their authority and violating the Administrative Procedure Act.
The lawsuit says the doctors &#;have been pressured, unable to prescribe medication, and threatened with or subjected to professional discipline.&#;
Bowden, for example, began recommending ivermectin to treat Covid in early and, according to the suit, was &#;derided by Houston Methodist Hospital and forced to resign her privileges there as a result.&#; Marik was forced to resign his positions at Eastern Virginia Medical School and Sentara Norfolk General Hospital for promoting the use of ivermectin after the FDA&#;s actions, according to the lawsuit.
The FDA told CNN on Wednesday that the lawsuit challenged its authority to issue a Consumer Update in March , several tweets and other social media posts from and that linked to the article, and two FAQs posted in , which the FDA said have &#;already been retired from the agency&#;s website.&#; The posts and other materials will be removed and archived as required by law.
Initially, the FDA claimed sovereign immunity, and a lower court judge in Texas dismissed the suit. The doctors appealed the case to the 5th Circuit, which reinstated the lawsuit last year, and its judges heard arguments last month.
Lawyers representing the doctors said in a statement posted on Boyden Gray PLLC&#;s website that the FDA &#;has agreed to delete its most viral social media campaign of all time&#; and claimed that the FDA&#;s advice about the off-label use of ivermectin was &#;unlawful.&#;
&#;Today&#;s settlement with the FDA is a major win for the doctor-patient relationship,&#; Marik said in the statement. &#;It vindicates our position that the FDA overstepped its regulatory authority by trying to dictate appropriate medical care.&#;
Independent presidential candidate Robert F. Kennedy Jr. posted on X, formerly Twitter, on Wednesday that the FDA &#;is biased against many low-cost, generic, and/or natural therapies&#; and implied that the FDA is in league with the pharmaceutical industry.
For more information, please visit Ivermectin Api Factory from China.